Pular para o conteúdo principal
Ranking Invest

CTMX - CytomX Therapeutics, Inc.

Segmento: HealthcareCytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Análise Ranking Invest

Valor de Mercado
$ 514.24 Mi
IVR
0.46Índice proprietário de comparação relativa: 0,46.
IVR2
-0.13Leitura proprietária complementar: -13%.
MLL
-0.13Leitura proprietária complementar: -13%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 302.07 Mi

Dívida Líquida

-$ 17.22 Mi

L4T

-$ 79.65 Mi

MM4T

-1468.10%

Indicadores Básicos

ROE

-26.37%

Índices de Previsibilidade

Receita Líquida

F0.54

Lucro

F2.94

Margem

E1.70

Índices de Tendência

Receita Líquida

D-2.60

Lucro

D-0.76

Margem

E-2.22

Índices de Endividamento

DIV/PAT

-0.06

DIV/L4T

0.22

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.